TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

4A.41 Edwards CN et al. Prevention and treatment of leptospirosis. Expert Rev Anti Infect Ther 2004;2: 293-8. 4A.42 Bharti AR et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 2003;3: 757-71. 4A.43 Clark RP et al. Prevention of Lyme disease and other tick-borne infections. Infect Dis Clin North Am 2008;22:381-96. 4A.44 Nadelman RB et al. Reinfection in patients with Lyme disease. Clin Infect Dis 2007;45:1032-8. 4A.45 Wormser GP et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-134. 4A.46 Nadelman RB et al. Prophylaxis with single dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001;345:79-84. 4A.47 Shapiro ED. Doxycycline for tick bites, not for everyone. N Engl J Med 2001;345:133-4. 4A.48 American Academy of Pediatrics Committee on Infectious Diseases. Prevention of Lyme disease. Pediatrics 2000;105:142-7. 4A.49 Gammons M et al. Tick removal. Am Fam Physician 2002;66:643-5. 4A.50 American Academy of Pediatrics Committee on Infectious Diseases. Haemophilus influenzae infections. Red Book 2009;28:314-21. 4A.51 Girgis N et al. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J 1998;17:816-9. 4A.52 Girgis N et al. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J 1998;17:816-9. 4A.53 American Academy of Pediatrics Committee on Infectious Diseases. Meningococcal infections. Red Book 2009;28:455-63. 4A.54 Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Morb Mortal Wkly Rep 2005;54(RR-7):1-21. 4A.55 Memish ZA. Meningococcal disease and travel. Clin Infect Dis 2002;34:84-90. 4A.56 Simmons G et al. Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria meningitidis. J Antimicrob Chemother 2000;45:909-11. 4A.57 Fraser A et al. Prophylactic use of antibiotics for prevention of meningococcal infections: review and meta-analysis of randomised trials. Eur J Clin Microbiol Infect Dis 2005;24:172-81. 4A.58 Gardner P. Prevention of meningococcal disease. N Engl J Med 2006;355:1466-73. 4A.59 Fraser A et al. Antibiotics for preventing meningococcal disease. Cochrane Database Syst Rev 2006;4:CD004785. 4A.60 Bucaneve G et al. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer Suppl 2007;5:5-12. 4A.61 Schlesinger A et al. Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:97-107. 4A.62 Gafter-Gvili A et al. Meta-analysis: antibiotic propylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95. 4A.63 Bucaneve G et al. Levofloxacin to prevent bacterial infections in patients with cancer and neutropenia. N Engl J Med 2005;353:977-87. 4A.64 Cullen M et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-98. 4A.65 Reuter S et al. Impact of fluoroquinolone prophylaxis on reduced infection related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005;40:1087-93. 4A.66 Zinner SH. Fluoroquinolone prophylaxis in patients with neutropenia. Clin Infect Dis 2005;40:1094-5. 4A.67 Cornely OA et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59. 4A.68 Ullmann AJ et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47. 4A.69 Bai Y et al. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol 2008;103:104-10. 4A.70 Nathens AB et al. Management of the critically ill patient with severe acute panceratitis. Crit Care Med 2004;32:2524-36. 4A.71 Dellinger EP et al. Early antibiotic treatment for severe acute necrotizing pancreatitis. A randomized, double-blind, placebo-controlled trial. Ann Surg 2007;245:674-83. 4A.72 Villatoro E et al. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2006;4:CD002941. 4A.73 Isenmann R et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo controlled, double blind trial. Gastroenterology 2004;126:997-1004. 4A.74 Isenmann R et al. Prevention of infectious complications in severe acute pancreatitis with systemic antibiotics: where are we now? Expert Rev Anti Infect Ther 2005;3:393-401. 4A.75 Fernández J et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24. 4A.76 Terg R et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized placebo-controlled study. J Hepatol 2008;48:774-9. 4A.77 Pastore Celentano L et al. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005;24:761-5. 4A.78 Altunaiji S et al. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007;3: CD004404. 4A.79 Singh M et al. Whooping cough: the current scene. Chest 2006;130:1547-53. 4A.80 Watanabe M et al. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti Infect Ther 2004;2:447-54. 4A.81 Centers for Disease Control and Prevention (CDC). Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. Morb Mortal Wkly Rep 2005;54(RR-14):1-16. 4A.82 Wirsing von König CH et al. Pertussis of adults and infants. Lancet Infect Dis 2002;2:744-50. 4A.83 Hewlett EL et al. Pertussis – not just for kids. N Engl J Med 2005;352:1215-22. 4A.84 American Academy of Pediatrics Committee on Infectious Diseases. Pertussis (whooping cough). Red Book 2009;28:504-19. 4A.85 Forsyth K. Pertussis, still a formidable foe. Clin Infect Dis 2007;45:1487-91. 4A.86 Mattoo S et al. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326-
82. 4A.87 de Smet AM et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009;360:20-31. 4A.88 Wilhelm J et al. Selective decontamination of the digestive tract and oropharynx: new findings for an old approach still under discussion. Expert Rev Anti Infect Ther 2009;7:399-402. 4A.89 Coffin SE et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(suppl. 1):S31-40. 4A.90 Craven DE. Preventing ventilator-associated pneumonia in adults: sowing seeds of change. Chest 2006;130:251-60. 4A.91 Collard HR et al. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann Intern Med 2003;138:494-501. 4A.92 Chan EY et al. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. Br Med J 2007;334:889-99. 4A.93 de Smet AM et al. Selective decontamination of the digestive tract. Curr Opin Infect Dis 2008;21: 179-83. 4A.94 Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004;32:1396-405. 4A.956 Dodek P et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med 2004;141:305-13. 4A.96 Koeman M et al. Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 2006;173:1348-55. 4A.97 Chan EY et al. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. Br Med J 2007;334:889-99. 4A.98 Wip C et al. Bundles to prevent ventilator-associated pneumonia: how valuable are they? Curr Opin Infect Dis 2009;22:159-66. 4A.99 Carapetis JR et al. Acute rheumatic fever. Lancet 2005;366:155-68. 4A.100 Gilad J et al. Prevention of catheter-related bloodstream infections in the neonatal intensive care setting. Expert Rev Anti Infect Ther 2006;4:861-73. 4A.101 Bhutta A et al. Reduction of bloodstream infections associated with catheters in paediatric intensive care unit: stepwise approach. Br Med J 2007;334:362-5. 4A.102 Pronovost P et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-32. 4A.103 Wenzel RP et al. Team-based prevention of catheter-related infections. N Engl J Med 2006;355: 2781-3. 4A.104 Raad I et al. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 2007;7:645-57. 4A.105 Gilad J et al. Prevention of catheter-related bloodstream infections in the neonatal intensive care unit setting. Expert Rev Anti Infect Ther 2006;4:861-73. 4A.106 Bhutta A et al. Reduction of bloodstream infections associated with catheters in paediatric intensive care unit: stepwise approach. Br Med J 2007;334:362-5. 4A.107 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention of intravascular catheter-related infections. Morb Mortal Wkly Rep 2002;51(RR-10):1-29. 4A.108 Crnich CJ et al. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. Part I: pathogenesis and short-term devices. Clin Infect Dis 2002;34:1232-42. 4A.109 Crnich CJ et al. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. Part II: long-term devices. Clin Infect Dis 2002;34:1362-8. 4A.110 Marshall J et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(suppl. 1):S22-30. 4A.111 O‘Grady NP et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2002;35:1281-307. 4A.112 McGee DC et al. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123-33. 4A.113 Echevarria-Guanilo ME et al. Preventing infections due to intravascular catheters in burn victims. Expert Rev Anti Infect Ther 2009;7:1081-6. 4A.114 Rupp ME et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central-catheter related infections. A randomized, controlled trial. Ann Intern Med 2005;143:570. 4A.115 Kaufman M et al. Care of the adolescent sexual assault victim. Pediatrics 2008;122:462-70. 4A.116 Centers for Disease Control and prevention (CDC). Sexually transmitted diseases. Treatment guidelines 2006. Morb Mortal Wkly Rep 2006;55(RR-11):1-94. 4A.117 Beck-Sagué CM et al. Sexually transmitted diseases in abused children and adolescent and adult victims of rape: review of selected literature. Clin Infect Dis 1999;28(suppl. 1):S74-83. 4A.118 Welch J et al. Rape and sexual assault. Br Med J 2007;334:1154-8. 4A.119 Low N et al. Global control of sexually transmitted infections. Lancet 2006;368:2001-16. 4A.120 Golden MR et al. Innovative approaches to the prevention and control of bacterial sexually transmitted infections. Infect Dis Clin North Am 2005;19:513-40. 4A.121 American Academy of Pediatrics Committee on Infectious Diseases. Sexual victimization and STIs. Red Book 2009;28:167-72. 4A.122 Groep ter Opsporing, Studie en Preventie van de Infecties in de Ziekenhuizen (GOSPIZ). Richtlijnen voor de beheersing en preventie van overdracht van methicilline-resistente Staphylococcus aureus (MRSA) in Belgische ziekenhuizen. Available at: http://www.belgian infectioncontrolsociety.be/index. php?page=mrsa&hl=nl_NL. Accessed on August 5 th 2010. 4A.123 Groupement pour le Dépistage, l‘Etude et la Prévention des Infections Hospitalières (GDEPIH). Recommandations pour le contrôle et la prévention de la transmission de Staphylococcus aureus résistant à la méthicilline dans les hôpitaux belges. Available at: http://www. belgian infectioncontrolsocie ty. be/index.php?page=mrsa&hl=fr_FR. Accessed on August 5 th 210. 4A.124 Groep ter Opsporing, Studie en Preventie van de Infecties in de Ziekenhuizen (GOSPIZ). Richtlijnen ter preventie van overdracht van methicilline-resistente Staphylococcus aureus (MRSA) in woon- en zorgcentra. Available at: http://www.belgian infection controlsociety.be/ index.php?page=mrsa&hl=nl
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88:
1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90:
21.358 Calabrese LH et al. Viral Ar
Page 91 and 92:
24. 21.452 Jeha LE et al. Long term
Page 93 and 94:
induced functional androgen deficie
Page 95 and 96:
25A.27 Conseil Supérieur de la San
Page 97 and 98:
product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?